About Ablative Solutions
Ablative Solutions is a Healthcare company based in Kalamazoo (United States) founded in 2011. It operates as an a catheter-based renal denervation system for hypertension treatment is developed. Ablative Solutions has raised $303.65 million across 13 funding rounds from investors including Novus Life Sciences, Gilde Healthcare and Invus. The company has 24 employees. Ablative Solutions offers products and services including Peregrine System. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is ABLATIVE SOLUTIONS INC. Its competitors include ReCor Medical, Brattea, Autonomix, Kalos Medical and Maya Medical and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Ablative Solutions was founded in 2011 and is located in Kalamazoo, United States. Renal denervation technologies are developed by the company within the medical device sector to address hypertension. A catheter-based method is used to deliver diagnostic and therapeutic agents to the perivascular space around peripheral blood vessels. The Peregrine system is being evaluated clinically for hypertension management. Operations focus on interventional cardiology solutions.
- Headquarters Kalamazoo, United States
- Employees 24
- SectorsHealthcare
- Website ablativesolutions.com
- Social LinkedIn
- Legal Name Ablative Solutions Inc.
- Total Equity Funding$303.65M (USD)
in 13 rounds
- Latest Funding Round$10.41M (USD), Series D
Nov 2025
- InvestorsNovus Life Sciences
& 5 more
- Employee Count24
Products & Services of Ablative Solutions
Ablative Solutions offers a comprehensive portfolio of products and services, including Peregrine System.
Investigational kit for renal denervation to treat hypertension in clinical trials
Funding Insights of Ablative Solutions
Ablative Solutions has successfully raised a total of $303.65M across 13 strategic funding rounds. The most recent funding activity was a Series D round of $10.41 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $303.65M
- Total Rounds 13
- Last Round Series D — $10.41M
- First Round $3.05M
(Mar 2012)
- Investors Count 6
Latest 10 of 13 funding rounds of Ablative Solutions with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2025 | $10.41M | Series D | – | – | – |
| Dec 2024 | $37.16M | Series D | – | – | – |
| Mar 2023 | $29.33M | Series D | – | – | – |
| Jun 2022 | $91.4M | Series D | – | – | |
| Jan 2019 | $77M | Series D | – | Gilde Healthcare, BioStar Capital | |
| Jan 2018 | $4.01M | Series C | – | – | – |
| Mar 2017 | $11.38M | Series C | – | – | – |
| Nov 2015 | $2.46M | Series B | – | – | – |
| Jan 2015 | $14.59M | Series B | – | Charter Capital Partners | |
| Feb 2014 | $9.5M | Series B | – | BioStar Capital |
6 investors in total: 6 institutional.
Investors in Ablative Solutions
Ablative Solutions has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Novus Life Sciences, Gilde Healthcare and Invus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Healthtech startups are funded by BioStar Capital's venture capital efforts. | – | biostarcapital.com | Charlevoix, United States | |
- | – | biostar.capital | - | |
Charter Capital Partners is engaged in M&A advisory and investment solutions. | 1989 | chartercapitalpartners.com | Grand Rapids, United States | |
Provider of orthobiologic solutions | 2014 | novusls.com | Sha Tin, China |
Investor details for Ablative Solutions
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ablative Solutions
25 people are tracked at Ablative Solutions (3 in leadership, 14 in board & advisors, 8 in team); the tracked headcount is 24.
| Name | Role | Group |
|---|---|---|
Tim Fischell | Chief Medical Officer | Leadership |
Sidu Gapara | Director Clinical Affairs | Leadership |
Kristine Canavan | VP, Regulatory Affairs | Leadership |
Paul Buckman | Director | Board & advisors |
Geoff Pardo | Director | Board & advisors |
Michael Fulton | Director | Board & advisors |
David Fischell | Director | Board & advisors |
Atul Pathak | Scientific Advisor | Board & advisors |
Melvin Lobo | Scientific Advisor | Board & advisors |
Felix Mahfoud | Scientific Advisor | Board & advisors |
Michael Weber | Scientific Advisor | Board & advisors |
Andrew Tochterman | Director | Board & advisors |
Roland E. Schmieder | Scientific Advisor | Board & advisors |
Alexandre Persu | Scientific Advisor | Board & advisors |
David E. Kandzari | Scientific Advisor | Board & advisors |
Ron Bache | Director | Board & advisors |
John Kerschen | Director | Board & advisors |
Buket Karakaya Husemann | Clinical Trial Manager EU | Team |
Cassie Miller | Sr. Clinical Trial Manager | Team |
Majid Fassi | EU Therapy Development Manager | Team |
5 more people are available in the full profile.
Complete people profiles for Ablative Solutions
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ablative Solutions
3 dated milestones of Ablative Solutions across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Ablative Solutions is founded.
- Funding First funding round of $3.1M.
- Funding Latest funding round, Series D, of $10.4M.
Competitors of Ablative Solutions
Ablative Solutions has 9 listed competitors in our database, 8 of them funded. They include ReCor Medical, Brattea, Autonomix, Kalos Medical and Maya Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| recormedical.com | 2009 | Palo Alto, United States | $15M | 93 | Ultrasound-based renal denervation is applied for hypertension treatment. | |
| brattea.com | 2013 | Xuhui, China | $15.2M | – | Developer of a medical device for the treatment of hypertension | |
| autonomix.com | 2014 | The Woodlands, United States | $8.2M | – | Minimally invasive neural monitoring and treatment devices are developed. | |
| kalosmedical.com | 2015 | Suwon-si, South Korea | – | – | Developer of medical devices for the treatment of hypertension & other chronic diseases | |
| maya-medical.com | 2010 | Campbell, United States | $6.92M | – | Catheter based ablative technology for renal denervation to treat hypertension | |
| konamedical.com | 2009 | Issaquah, United States | $73.66M | 39 | Provides ultrasound-based renal denervation solutions for hypertension treatment. | |
| vessixvascular.com | 2003 | Laguna Hills, United States | $27.7M | 10 | Thermoplasty technology for occlusive peripheral vascular diseases is developed. | |
| verve-medical.com | 2011 | Santa Barbara, United States | $3.63M | – | Renal denervation treatments for hypertension are developed by Verve Medical. | |
| symplesurgical.com | 2012 | Menlo Park, United States | $3.4M | – | Microwave ablation is developed for hypertension treatment. |
Detailed competitors of Ablative Solutions
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ablative Solutions
The website of Ablative Solutions (ablativesolutions.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 3.7% vs previous month
Top companies in Cardiac and Vascular Disorders
10 companies that operate in the same segment as Ablative Solutions (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | – | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ablative Solutions
Complete news archive for Ablative Solutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ablative Solutions
Ablative Solutions was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Ablative Solutions is headquartered in Kalamazoo, United States. It is registered at Kalamazoo, Michigan, United States.
Ablative Solutions is a funded company, having raised a total of $303.65M across 13 funding rounds to date. The company's 1st funding round was a Series B of $9.5M, raised on Mar 2012.
Ablative Solutions has 24 employees.
Ablative Solutions was founded in 2011 and is located in Kalamazoo, United States. Renal denervation technologies are developed by the company within the medical device sector to address hypertension. A catheter-based method is used to deliver diagnostic and therapeutic agents to the perivascular space around peripheral blood vessels. The Peregrine system is being evaluated clinically for hypertension management. Operations focus on interventional cardiology solutions.
Ablative Solutions's top competitors include ReCor Medical, Autonomix and Maya Medical.
Ablative Solutions offers Peregrine System.
Ablative Solutions has 6 investors. Key investors include Novus Life Sciences, Gilde Healthcare, Invus, BioStar Capital, and Charter Capital Partners.
Ablative Solutions operates through Ablative Solutions Inc..